VGX-3100 + Placebo
Phase 3Completed 0 watching 0 views this weekπ Rising
69
Development Stage
β
Pre-clinicalβ
Phase 1β
Phase 24
Phase 35
ApprovedIndication / Disease
Cervical Dysplasia
Conditions
Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
Trial Timeline
Jun 28, 2017 β Apr 6, 2021
NCT ID
NCT03185013About VGX-3100 + Placebo
VGX-3100 + Placebo is a phase 3 stage product being developed by Inovio Pharmaceuticals for Cervical Dysplasia. The current trial status is completed. This product is registered under clinical trial identifier NCT03185013. Target conditions include Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03185013 | Phase 3 | Completed |
Competing Products
20 competing products in Cervical Dysplasia